Skip to content
Peptide research

PACAP

Also known as PACAP-38 · Pituitary Adenylate Cyclase-Activating Peptide
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

PACAP is a naturally occurring 38-amino-acid neuropeptide marketed for neuroprotection after stroke and brain injury. Evidence is almost entirely animal-based: moderate data show reduced stroke damage, while Parkinson's and Huntington's claims rest on weaker findings, and human evidence is essentially absent. Its mechanism reliably triggers migraine and low blood pressure. Not an approved drug in the US; supply is unregulated research-grade material.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Potent neuroprotection against ischemic brain injury (40-60% infarct reduction in animal models)

    Medium

    Consistently reduces stroke damage in rodent models over 25 years of study; no human trials exist.

  • Protection of striatal neurons in Huntington's disease models via PAC1R/ERK/Akt signaling

    Low

    Protects striatal neurons in a small number of Huntington's mouse studies; no human data.

  • Anti-apoptotic effects via Bcl-2 upregulation and cytochrome c suppression

    Medium

    Well-replicated mechanism in animal and cell studies; not yet confirmed as a clinical benefit.

Evidence limits

Evidence Level
Strong Preclinical / Early Clinical

PACAP has an exceptionally strong preclinical evidence base with >3,000 publications demonstrating neuroprotection across stroke, traumatic brain injury, neurodegeneration, and retinal disease models. Clinical research has primarily focused on PACAP's role in migraine pathophysiology, where it has been validated as a therapeutic target. Anti-PACAP-ligand antibody LY3451838 (Eli Lilly) completed Phase 2 for migraine prevention. Direct therapeutic use of PACAP for neuroprotection has not yet entered clinical trials due to challenges with delivery and its vasodilatory/migraine-triggering side effects.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(3)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Migraine/headache induction via vasodilation

    High
  • Systemic vasodilation and hypotension

    Moderate
  • Very short half-life limiting therapeutic window

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.